ALK (F1174L)-NPM1
Sign in to save this workspaceALK · Variant type: fusion · HGVS: p.F1174L · Fusion partner: NPM1 (F1174L)
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ceritinib | 99.9% | 0.1% | 95.44 |
| 2 | Crizotinib | 99.3% | 0.7% | 91.39 |
| 3 | Gilteritinib | 99.2% | 0.8% | 88.97 |
| 4 | Brigatinib | 99.2% | 0.8% | 82.96 |
| 5 | Lorlatinib | 99.0% | 0.9% | 97.24 |
| 6 | Entrectinib | 98.8% | 1.2% | 93.69 |
| 7 | Repotrectinib | 98.4% | 1.6% | 84.21 |
| 8 | Alectinib | 98.2% | 1.8% | 95.49 |
| 9 | Nintedanib | 87.4% | 12.6% | 90.23 |
| 10 | Sunitinib | 84.7% | 15.3% | 91.73 |
| 11 | Bosutinib | 84.3% | 15.8% | 87.22 |
| 12 | Osimertinib | 76.1% | 23.9% | 97.24 |
| 13 | Pralsetinib | 68.3% | 31.7% | 93.43 |
| 14 | Alpelisib | 67.2% | 32.8% | 97.22 |
| 15 | Ruxolitinib | 64.4% | 35.6% | 98.25 |
| 16 | Pacritinib | 61.2% | 38.8% | 88.64 |
| 17 | Axitinib | 44.6% | 55.4% | 93.23 |
| 18 | Baricitinib | 40.9% | 59.1% | 97.99 |
| 19 | Defactinib | 33.6% | 66.4% | 92.68 |
| 20 | Darovasertib | 32.6% | 67.4% | 96.99 |
| 21 | Erlotinib | 31.5% | 68.5% | 99.75 |
| 22 | Fedratinib | 26.8% | 73.2% | 96.21 |
| 23 | Lazertinib | 25.8% | 74.2% | 97.47 |
| 24 | Afatinib | 25.4% | 74.6% | 98.50 |
| 25 | Tepotinib | 25.0% | 75.0% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ceritinib | 99.9% | 98.3% | +1.6% |
| Crizotinib | 99.3% | 97.7% | +1.6% |
| Gilteritinib | 99.2% | 99.5% | -0.2% |
| Brigatinib | 99.2% | 99.2% | -0.0% |
| Lorlatinib | 99.0% | 97.2% | +1.8% |
| Entrectinib | 98.8% | 98.8% | -0.1% |
| Repotrectinib | 98.4% | 99.4% | -0.9% |
| Alectinib | 98.2% | 98.6% | -0.3% |
| Nintedanib | 87.4% | 84.9% | +2.5% |
| Sunitinib | 84.7% | 87.7% | -3.0% |
| Bosutinib | 84.3% | 75.1% | +9.1% |
| Osimertinib | 76.1% | 80.5% | -4.4% |
| Pralsetinib | 68.3% | 82.6% | -14.3% |
| Alpelisib | 67.2% | 80.7% | -13.4% |
| Ruxolitinib | 64.4% | 52.1% | +12.3% |
| Pacritinib | 61.2% | 55.3% | +5.9% |
| Axitinib | 44.6% | — | — |
| Baricitinib | 40.9% | 46.4% | -5.4% |
| Defactinib | 33.6% | — | — |
| Darovasertib | 32.6% | — | — |
| Erlotinib | 31.5% | — | — |
| Fedratinib | 26.8% | — | — |
| Lazertinib | 25.8% | 46.3% | -20.4% |
| Afatinib | 25.4% | — | — |
| Tepotinib | 25.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Neuroblastoma | Brain/CNS | ref |
| neuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| mesothelioma_pleura | Lung | ref |
| carcinoma_kidney | Kidney | ref |
| carcinoma_lung | Lung | ref |
| neuroblastic_tumour_autonomic_ganglia | Brain/CNS | ref |
| carcinoma_skin | Skin | ref |
| ganglioneuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| inflammatory_myofibroblastic_tumour_soft_tissue | Soft Tissue | ref |
| carcinoma_salivary_gland | Salivary Gland | ref |
| carcinoma_prostate | Prostate | ref |
| NBL-US | Brain/CNS | ref |
| NB | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.1ms